Testosterone recovery post-ADT is influenced by treatment duration, baseline testosterone levels, and patient age. Younger patients and those with higher baseline testosterone levels recover more ...

Androgen-deprivation therapy (ADT) has become the mainstay of treatment for metastatic prostate cancer. ADT's testosterone depletion, however, leads to side effects that impair health-related ...

Men with prostate cancer who were treated with the GnRH agonist leuprolide had significantly more coronary artery plaque progression than those receiving the GnRH antagonist relugolix.

Researchers have found in a new study that among men with prostate cancer undergoing androgen deprivation therapy, use of oxybutynin 5 mg twice daily significantly reduced the frequency ...

Men receiving treatment for prostate cancer often face challenges that extend well beyond the disease itself. A new study led ...

The addition of Zytiga (abiraterone) to Truqap (capivasertib) significantly prolonged radiographic progression-free survival (rPFS) in patients with PTEN-deficient metastatic hormone-sensitive ...

Outcomes of prostate cancer patients hospitalized with viral respiratory illnesses: A national population-based study. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...

A central aim of prostate cancer treatment is to prolong survival, but trials often overlook another key goal: Improving — or at least maintaining — quality of life (QoL). The recent American Society ...

Two types of androgen deprivation therapy (ADT) had different effects on coronary atherosclerosis in a small randomized trial of men with prostate cancer. Significantly more coronary artery plaque ...